Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: EPOCH Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Kaempferol Absorption and Pharmacokinetics Evaluation

NCT07322406
View directory record Official record
Conditions
No Disease, Mitochondria Health, Longevity, Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult, Healthy Volunteers
Interventions
Kaempferol
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Phase 1 Interventional

Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer

NCT01884584
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Indocyanine green (ICG)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

NCT01235585
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, bitopertin [RO4917838]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
25
States / cities
Carson, California • Garden Grove, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

NCT05824143
View directory record Official record
Conditions
Healthy Participants
Interventions
Darigabat, Carbamazepine
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Not applicable Interventional

Cranial Electrotherapy for Military Beneficiaries With Restless Legs Syndrome

NCT02419014
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Active CES Device Alpha-Stim®, Sham Device
Device
Lead sponsor
Tripler Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment

NCT03097614
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
TrueTear
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Not applicable Interventional

Effect of Prolonged Nightly Fasting on Immunotherapy Outcomes in HNSCC - Role of Gut Microbiome

NCT05083416
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Prolonged Nightly Fasting, Regular Eating pattern
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 15, 2026, 5:46 AM EDT
Completed No phase listed Observational Results available

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

NCT05127304
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol, Tiotropium Bromide/Olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
11,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 15, 2026, 5:46 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

High-Intensity Interval Training and Regulatory T Cells

NCT04774484
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
High Intensity Interval Training
Other
Lead sponsor
Francesc Marti
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 15, 2026, 5:46 AM EDT
Not yet recruiting Not applicable Interventional

Theoretically Informed Behavioral Intervention

NCT06580184
View directory record Official record
Conditions
HIV, CVD, Metabolic Disease
Interventions
LEARN 2 Platform
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Orange, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 15, 2026, 5:46 AM EDT
Recruiting Not applicable Interventional

Support Via Online Social Networks to Promote Safe Infant Care Practices

NCT05767658
View directory record Official record
Conditions
Breastfeeding, Infant Death, Sudden Infant Death Syndrome Without Mention of Autopsy
Interventions
Safe Sleep, Breastfeeding, Early Brain Development and Parent-Child Relationships
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
Female only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Phase 4 Interventional Results available

Naltrexone for Heavy Drinking in Young Adults

NCT00568958
View directory record Official record
Conditions
Alcohol Consumption, Alcoholic Intoxication, Alcoholism, Alcohol-induced Disorders
Interventions
BASICS counseling, naltrexone, placebo naltrexone
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 25 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 15, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional Results available

A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part II

NCT02707055
View directory record Official record
Conditions
Alcoholism
Interventions
PF-05190457, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Phase 4 Interventional Results available

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

NCT04757584
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions
Beta blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects

NCT04086238
View directory record Official record
Conditions
Healthy
Interventions
Decitabine
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Phase 1 Interventional

A Proof-of-Concept Study of Minocycline in Autism

NCT04031755
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism
Interventions
Minocycline, Placebos
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 22 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Columbia, Missouri • Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Not applicable Interventional

GI Alpha-Gal Study

NCT06268717
View directory record Official record
Conditions
Alpha-Gal Syndrome, Irritable Bowel Syndrome, Diarrhea, Abdominal Pain, Vomiting
Interventions
Ground pork containing alpha-gal, Pork meat not containing alpha-gal
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 15, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional Results available

RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

NCT00667017
View directory record Official record
Conditions
Lymphoma
Interventions
RFT5-dgA immunotoxin, fluorescence activated cell sorting, immunohistochemistry staining method
Biological · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 15, 2026, 5:46 AM EDT
Withdrawn Phase 2 Interventional

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

NCT05974293
View directory record Official record
Conditions
NMO Spectrum Disorder, Spasticity, Muscle
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Michael, Levy M.D.,Ph.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 15, 2026, 5:46 AM EDT
Recruiting Not applicable Interventional

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

NCT06258993
View directory record Official record
Conditions
Breast Cancer
Interventions
Core Exercise Promotion Program, Affect-based exercise prescription, Effort-based exercise prescription
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Not applicable Interventional

Transdiagnostic Group Therapy (GBAT) for Autistic Adults With Personalized Therapeutics

NCT05512221
View directory record Official record
Conditions
GBAT+Individual, GBAT+Engagement Booster, GBAT+Both
Interventions
GBAT+I, GBAT+E - Phase I, Watchful Waiting and Groups - Phase 2, GBAT+IE
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 15, 2026, 5:46 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

NCT07225114
View directory record Official record
Conditions
Breast Cancer, Kidney Neoplasms, Liver Neoplasms
Interventions
contrast agent perflutren lipid, Ultrasound Imaging
Drug · Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Interrupting Prolonged Sitting With Intermittent Exercise on Postprandial Lipemia

NCT03856606
View directory record Official record
Conditions
Metabolic Syndrome X, Atherosclerosis, Insulin Resistance, Hyperinsulinism, Glucose Metabolism Disorders, Metabolic Disease, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions
Prolonged sitting without exercise, Prolonged sitting with interval exercise
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 15, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 and Theophylline in Healthy Subjects

NCT01263106
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Theophylline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2019 · Synced Sep 15, 2026, 5:46 AM EDT